OPKO Health Q4 revenue $148.5M, net loss $31.3M; Regeneron deal >$1B

OPKO HEALTH, INC.

2025-FY EPS reported -$0.30 revenue$606,879,000

Q4 revenue $148.5M (down 19% YoY); net loss $31.3M ($0.04/share) vs $14.0M income in Q4 2024.
Regeneron collaboration for multispecific antibodies: upfront + milestones >$200M per program, total >$1B.
Pharmaceuticals revenue $43.7M (+17% YoY); NGENLA profit share $12.5M, Rayaldee $8.8M.
Diagnostics revenue $71.1M (down 31% YoY) on asset sale; operating loss improved to $18.3M from $21.7M.
FY 2026 guidance: total revenue $530-560M; total costs $725-750M; R&D $125-135M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.